Testing new clotting factor for people with untreated or minimally treated Hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Hemophilia A that is severe (very low factor activity: FVIII below 1%)
- You (or your doctor) have already decided to start an Octapharma FVIII treatment before joining the study
- You either have never received FVIII clotting factor before, or have had fewer than 5 exposure days
- You have no history of an inhibitor to FVIII (an immune reaction that blocks the medicine), or you developed one only while using Octapharma FVIII and can continue it
- You are able to give informed consent (or a parent/legal guardian can sign for you)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Inno8 in people with haemophilia A. It looks at how different doses work in the body and may help improve treatment options.
This study tests a new medicine called denecimig (Mim8) for adults newly diagnosed with a rare bleeding disorder called acquired hemophilia A. If you have had a bleed that needs treatment, this trial could help you manage your condition.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This study tests a new medicine called SKP-0141 to see if it can safely treat and prevent bleeding in people with severe hemophilia A. It might help reduce the number of bleeds and improve quality of life.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
Hear when a new Haemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.